An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) — China ARCHES  

Metastatic Hormone Sensitive Prostate Cancer Clinical Trial

Official title: China ARCHES: A Multicenter, Phase 3, Randomized, Double-blind, Placebo Controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

Status Active, not recruiting

Clinical Trial Summary

The purpose of this study was to evaluate the efficacy and safety of enzalutamide plus androgen deprivation therapy (ADT) versus placebo plus ADT in Chinese subjects with metastatic hormone sensitive prostate cancer (mHSPC). The study was conducted in two phases: Double-Blind treatment phase and open-label phase.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Hypersensitivity
• Metastatic Hormone Sensitive Prostate Cancer
• Prostatic Neoplasms

• NCT number: NCT04076059
• Study type: Interventional
• Source: Astellas Pharma Inc
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: September 11, 2019
• Completion date: December 31, 2028